Posted August 13, 2016

Seller of Omega-3, Ginkgo, Vision Supplements & More Warned for Drug Claims

On July 22, 2016, the FDA issued a warning letter to Viva Nutraceuticals (J & E International Corporation) following a review of the company's website and promotional literature, which found statement made about its products, Eyestonia, Ginkgo Biloba 60mg, Golden Omega-3 Max, Indole-3-Carbinol 200mg, Liveria, L-Lysine 1000mg and ProsTac Softgel to be drug claims.

For example, Eyestonia was promoted with statements such as "Used in herbal medicine to help slow the progression of disorders of the eye, such as diabetic and hypertensive retinopathy as well as macular degeneration."  

(See ConsumerLab.com's Review of Vision Supplements for tests of related products.)

Golden Omega-3 Max was promoted with statements such as "Protects against cardiovascular diseases such as atherosclerosis, myocardial infarction, coronary heart disease, and arrhythmias."  

(See ConsumerLab.com's Fish Oil and Omega-3 Fatty Acid Supplements for tests of related products.)

Ginkgo Biloba 60mg was promoted with statements such as "Clinical benefits: ischemia, epilepsy, peripheral nerve damage, and dementia."  

(See ConsumerLab.com's Review of Gingko Biloba Supplements for tests of related products.)

L-Lysine 1000mg was promoted with statements such as "Helps to reduce the recurrence of herpes simplex virus (HSV) infection (e.g. cold sores)."  

(See ConsumerLab.com's Review of L-lysine Supplements for tests of related products.)

ProsTac Softgel was promoted with statements such as "[P]rotect against development of cancerous prostate cell lines."  

(See ConsumerLab.com's Review of Prostate Supplements for tests of related products.)

To read the FDA's warning letter, use the link below.